TG Therapeutics Future Growth
Future criteria checks 4/6
TG Therapeutics is forecast to grow earnings and revenue by 5.3% and 26.7% per annum respectively. EPS is expected to grow by 3.3% per annum. Return on equity is forecast to be 35% in 3 years.
Key information
5.3%
Earnings growth rate
3.26%
EPS growth rate
| Biotechs earnings growth | 23.9% |
| Revenue growth rate | 26.7% |
| Future return on equity | 35.04% |
| Analyst coverage | Good |
| Last updated | 07 Nov 2025 |
Recent future growth updates
Recent updates
TG Therapeutics: Concerns About Slowing Growth And New Competition
Nov 18TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Oct 23
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
Sep 30Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)
Jul 29TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 16Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Apr 09TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Mar 14Risks To Shareholder Returns Are Elevated At These Prices For TG Therapeutics, Inc. (NASDAQ:TGTX)
Mar 02TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry?
Jan 07Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1,140 | 396 | 402 | 597 | 6 |
| 12/31/2026 | 902 | 301 | 316 | 385 | 8 |
| 12/31/2025 | 606 | 468 | 437 | 503 | 8 |
| 9/30/2025 | 532 | 447 | -70 | -70 | N/A |
| 6/30/2025 | 454 | 60 | -59 | -59 | N/A |
| 3/31/2025 | 386 | 39 | -61 | -61 | N/A |
| 12/31/2024 | 329 | 23 | -41 | -41 | N/A |
| 9/30/2024 | 265 | -14 | -28 | -28 | N/A |
| 6/30/2024 | 347 | 96 | 68 | 68 | N/A |
| 3/31/2024 | 289 | 41 | 20 | 20 | N/A |
| 12/31/2023 | 234 | 13 | -31 | -31 | N/A |
| 9/30/2023 | 190 | -26 | -42 | -42 | N/A |
| 6/30/2023 | 24 | -176 | -160 | -160 | N/A |
| 3/31/2023 | 9 | -169 | -167 | -167 | N/A |
| 12/31/2022 | 3 | -224 | -176 | -176 | N/A |
| 9/30/2022 | 5 | -239 | -239 | -239 | N/A |
| 6/30/2022 | 7 | -288 | -272 | -272 | N/A |
| 3/31/2022 | 8 | -326 | -283 | -283 | N/A |
| 12/31/2021 | 7 | -348 | -296 | -296 | N/A |
| 9/30/2021 | 4 | -343 | -261 | -261 | N/A |
| 6/30/2021 | 2 | -345 | -251 | -250 | N/A |
| 3/31/2021 | 1 | -319 | -234 | -234 | N/A |
| 12/31/2020 | 0 | -279 | -215 | -215 | N/A |
| 9/30/2020 | 0 | -231 | -193 | -193 | N/A |
| 6/30/2020 | 0 | -206 | -170 | -170 | N/A |
| 3/31/2020 | 0 | -189 | -162 | -162 | N/A |
| 12/31/2019 | 0 | -173 | -133 | -133 | N/A |
| 9/30/2019 | 0 | -187 | -136 | -136 | N/A |
| 6/30/2019 | 0 | -159 | N/A | -136 | N/A |
| 3/31/2019 | 0 | -167 | N/A | -134 | N/A |
| 12/31/2018 | 0 | -173 | N/A | -129 | N/A |
| 9/30/2018 | 0 | -150 | N/A | -117 | N/A |
| 6/30/2018 | 0 | -148 | N/A | -107 | N/A |
| 3/31/2018 | 0 | -132 | N/A | -100 | N/A |
| 12/31/2017 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2017 | 0 | -111 | N/A | -89 | N/A |
| 6/30/2017 | 0 | -105 | N/A | -81 | N/A |
| 3/31/2017 | 0 | -92 | N/A | -67 | N/A |
| 12/31/2016 | 0 | -78 | N/A | -62 | N/A |
| 9/30/2016 | 0 | -72 | N/A | -57 | N/A |
| 6/30/2016 | 0 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 0 | -62 | N/A | -52 | N/A |
| 12/31/2015 | 0 | -63 | N/A | -45 | N/A |
| 9/30/2015 | 0 | -64 | N/A | -47 | N/A |
| 6/30/2015 | 0 | -68 | N/A | -44 | N/A |
| 3/31/2015 | 0 | -63 | N/A | -36 | N/A |
| 12/31/2014 | 0 | -56 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TGTX's forecast earnings growth (5.3% per year) is above the savings rate (3.3%).
Earnings vs Market: TGTX's earnings (5.3% per year) are forecast to grow slower than the US market (16.1% per year).
High Growth Earnings: TGTX's earnings are forecast to grow, but not significantly.
Revenue vs Market: TGTX's revenue (26.7% per year) is forecast to grow faster than the US market (10.5% per year).
High Growth Revenue: TGTX's revenue (26.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TGTX's Return on Equity is forecast to be high in 3 years time (35%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/03 09:42 |
| End of Day Share Price | 2025/12/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TG Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |